Key result
PIRB and its ligand ANGPTL2 negatively regulate platelet activation by suppressing collagen receptor glycoprotein VI and integrin αIIbβ3-mediated signaling.
Population
Mouse and human platelets, specifically PIRB intracellular domain deletion (PIRB-TM) mice
Comparison
PIRB intracellular domain deletion and ANGPTL2… vs Wild-type mice/platelets (implied)
Design
Preclinical
Authors
Loading...
PIRB/ANGPTL2 may offer a novel antiplatelet approach; leaves open translation from animal models to clinical thrombosis prevention.
Absolute Event Rate: 897% vs 612%
p-value: p=<0.01
PIRB and its ligand ANGPTL2 demonstrate antithrombotic properties by inhibiting key platelet activation signaling pathways, suggesting a potential novel target for antiplatelet therapy.
Fan et al. (2014) studied Platelet activation and thrombosis. PIRB deletion and ANGPTL2 treatment vs. Wild-type / Vehicle was evaluated on Platelet count (x 10^9/L) (p=<0.01). PIRB and its ligand ANGPTL2 negatively regulate platelet activation by suppressing collagen receptor glycoprotein VI and integrin αIIbβ3-mediated signaling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: